Name: Citius Oncology, Inc. (CTOR) Cash Flow Statement
Creator: FinSpry

Citius Oncology Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Citius Oncology, Inc. (CTOR) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 2025	Sep 2024	Sep 2023	Sep 2022
Operating Activities
Net Income	-24.76	-21.15	-12.70	-10.87
Deferred Income Tax	1.06	0.58	0.58	0.58
Stock Based Compensation	8.32	7.50	1.97	0.00
Change in Working Capital	9.89	13.20	10.16	4.86
Change in Inventory	-12.65	-2.13	0.00	0.00
Change in Accounts Payable	9.52	2.42	1.20	4.79
Change in Other Working Capital	13.02	12.91	8.96	9.53
Other Operating Activities	0.00	0.58	0.58	1.15
Net Cash from Operating Activities	-5.49	0.13	0.00	0.00
Investing Activities
Capital Expenditures	-5.75	-5.00	0.00	0.00
Sales/Maturities of Investments	0.00	-5.00	0.00	0.00
Net Cash from Investing Activities	-5.75	-5.00	0.00	0.00
Financing Activities
Common Stock Issued	15.17	0.00	0.00	0.00
Other Financing Activities	0.00	1.07	0.00	0.00
Net Cash from Financing Activities	15.17	4.87	0.00	0.00
Summary
Net Change in Cash	3.92	0.00	0.00	0.00
Cash at Beginning of Period	0.00	0.00	0.00	0.00
Cash at End of Period	3.92	0.00	0.00	0.00
Free Cash Flow	-11.24	-4.87	0.00	0.00
Supplemental Disclosures
Interest Paid	0.19	0.00	0.00	0.00